In Brief

Sen. Hatch on path to re-election; Senate passes FDA Safety and Innovation Act; DSM petitions FDA for folic acid fortification of masa flour; Nutrition 21 returns under new management; ZO Skin Health defends trademarks; more news In Brief.

Utah Republican Sen. Orrin Hatch cruised to a primary victory June 26 over Tea Party challenger Dan Liljenquist, virtually ensuring the supplement industry stalwart will remain in the Senate another six years. Hatch is the heavy favorite in November’s general election against Democrat and former Utah state senate leader Scott Howell. First elected to the Senate in 1977, Hatch plans to retire in 2018 at the end of his seventh term, when he will be 84 years old. He would begin 2013 as the Senate’s most senior Republican and third in overall chamber seniority. Hatch was an architect of the Dietary Supplement Health and Education Act and most recently pressured FDA on the new dietary ingredient notification draft guidance, which the agency has agreed to revise Also see "FDA Revision Of NDI Draft Guidance Starts With Grandfathered List" - Pink Sheet, 25 June, 2012..

The Senate passed the FDA Safety and Innovation Act by a 92-4 vote June 26 to reauthorize the agency’s prescription...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

How Could MFN Pricing Impact Commercial Market?

 
• By 

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.

COVID-19 mRNA Vaccine Labels Now Quantify Myocarditis Risk, But ACIP Wants Other Changes

 
• By 

New members of the CDC’s Advisory Committee on Immunization Practices suggested concerns beyond myocarditis, questioning whether test-negative observational studies are giving an incorrect picture of effectiveness.

Medicare’s Combo Products Negotiation Plan Conflicts With US FDA Standards, Firms Argue

 
• By 

The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.

US FDA’s ADHD Drug Relabeling Advances A MAHA Priority, Reviving Data Dispute

 

Extended-release stimulants will add a new ‘Limitation of Use’ about weight loss in children under 6 years, reflecting concerns about overuse from the Make America Healthy Again commission, a concern multiple studies did not find valid.

More from North America

Trump Administration Closer to Unprecedented Drug Price Transparency Requirements

 
• By 

New rules requiring more granular drug pricing data to be disclosed in machine-readable files will go into effect in 2026.

Orphan Drug Relief Still In Budget Bill But Uncertainty Remains

 
• By 

The budget reconciliation bill nears final passage without pharmacy benefit manager reforms or provisions that would facilitate access to cell and gene therapies for children, but its Medicaid cuts pose a significant threat to prescription drug access.

How Will Regulatory Filing Winds Blow Globally For Elevidys Following Patient Deaths?

 

Roche’s filing for Elevidys in the EU followed applications in Middle Eastern countries because those markets accept applications based on approval by the US Food and Drugs Administration.